Pfizer’s abrocitinib meets co-primary efficacy endpoints in phase 3 AD trial

This article was originally published here

The late-stage study assessed the safety and efficacy of abrocitinib in adult patients with the skin condition, who were also on background topical therapy. According to Pfizer, the

The post Pfizer’s abrocitinib meets co-primary efficacy endpoints in phase 3 AD trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply